Hillegaart V, Estival A, Ahlenius S
Department of Biochemical and Behavioral Pharmacology, Södertälje, Sweden.
Eur J Pharmacol. 1996 Jan 11;295(2-3):155-61. doi: 10.1016/0014-2999(95)00666-4.
The 5-HT1A and the 5-HT2A/C receptor agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (0.006-0.4 mg kg-1 s.c.) and (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (0.05-4.0 mg kg-1 s.c.), respectively, produced a similar stereotyped forward locomotion in rats, although the intensity of the behavioral change was considerably less with DOI. The stereotyped forward locomotion was accompanied by a slight decrease in total activity, suppression of rearing behavior and an increased activity in the periphery of the open-field arena. In support of receptor specificity, the effects of 8-OH-DPAT and DOI could be antagonised by pretreatment with the 5-HT1A/B and the 5-HT2A/C receptor antagonists (-)-pindolol (2 mg kg-1 s.c.) and ritanserin (2 mg kg-1 s.c.), respectively. In addition, (-)-pindolol, but not the selective beta-adrenoceptor antagonist betaxolol, markedly enhanced the behavioral effects produced by DOI. The nature of these specific actions and interactions in terms of pre- and post-synaptic serotonergic mechanisms remains an important question.
5-羟色胺1A受体和5-羟色胺2A/C受体激动剂8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)(0.006 - 0.4毫克/千克,皮下注射)和(±)-1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)(0.05 - 4.0毫克/千克,皮下注射)分别在大鼠中产生了类似的刻板向前运动,尽管DOI引起的行为变化强度要小得多。刻板向前运动伴随着总活动量略有下降、站立行为受到抑制以及旷场实验场地周边活动增加。为支持受体特异性,8-OH-DPAT和DOI的作用可分别被5-羟色胺1A/B受体拮抗剂(-)-吲哚洛尔(2毫克/千克,皮下注射)和5-羟色胺2A/C受体拮抗剂利坦色林(2毫克/千克,皮下注射)预处理所拮抗。此外,(-)-吲哚洛尔而非选择性β-肾上腺素能受体拮抗剂倍他洛尔显著增强了DOI产生的行为效应。就突触前和突触后血清素能机制而言,这些特定作用和相互作用的本质仍是一个重要问题。